Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Surveillance Markers of Utility for Recurrence After Neoadjuvant Chemotherapy for Breast Cancer

NCT02830282 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT02830282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02830282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Surveillance Markers of Utility for Recurrence After Neoadjuvant Chemotherapy for Breast Cancer
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Observational
Overall status
Completed
Start date
July 31, 2013
Completion date
March 16, 2018
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer